Government-Owned Inventions; Availability for Licensing, 79594 [2015-32096]
Download as PDF
<![CDATA[
79594
Federal Register / Vol. 80, No. 245 / Tuesday, December 22, 2015 / Notices
decision-making processes are
consistent with NEPA.
Need and Proposed Use of the
Information: Applicants must provide
information and assurance of
compliance with NEPA on the EID
checklist. This information is reviewed
in the Pre-Award stage.
Likely Respondents: HRSA applicants
applying for federal construction grants
and cooperative agreements.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
Number of
respondents
Form name
Number of
responses per
respondent
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
Total Estimated Annualized burden
hours:
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
NEPA EID Checklist ............................................................
1,350
1
1,350
1.0
1,350
Total ..............................................................................
1,350
1
1,350
1.0
1,350
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015–32004 Filed 12–21–15; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by emailing the
indicated licensing contact at the
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:21 Dec 21, 2015
Jkt 238001
National Heart, Lung, and Blood, Office
of Technology Transfer and
Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Metallic Nanoparticles for
Photothermal Therapy
Description of Technology: The
invention relates to the preparation and
application of 20–150nm metallic
nanoparticulate vesicles for
photothermal anti-cancer therapy. The
vesicles comprise metallic nanoparticles
covalently bound to a hydrophilic and
hydrophobic polymer. The preparation
method generally entails dispersing a
polymer-bound metallic nanoparticle in
an organic solvent, adding an aqueous
solution with a dispersing aid,
sonicating the mixture, and finally
removing the organic solvent until the
vesicle forms. The final vesicle is stable
wherein the metallic nanoparticle is
covalently bound to the hydrophobic
and hydrophilic polymer. By way of a
non-limiting example, an exemplary
vesicles can be one made from gold
nanorods coated with polyethylene
glycol and polylactic-co-glycolic acid
(AuNR@PEG/PLGA) in an oil-in-water
emulsion.
Potential Commercial Applications:
• Cancer therapy
• Tumor therapy
Competitive Advantages:
• Prolonged circulation
• High tumor accumulation
• Rapid excretion
• Enhanced photoacoustic signal
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
• Enhanced photothermal effect/cancer
therapy efficacy.
Development Stage:
• In vitro data
Inventors: Xiaoyuan (Shawn) Chen
and Jibin Song (both of NIBIB).
Intellectual Property: HHS Reference
No. E–158–2015/0–US–01.
• U.S. Provisional Patent Application
62/226,289 filed December 11, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Biomedical
Imaging and Bioengineering seeks
statements of capability or interest from
parties interested in collaborative
research to further develop and evaluate
metallic nanoparticle vesicles for cancer
phototherapy. For collaboration
opportunities, please contact Cecilia
Pazman, Ph.D. at
pazmance@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2015–32096 Filed 12–21–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Start-Up Option License: Potent and
Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 80, Number 245 (Tuesday, December 22, 2015)]
[Notices]
[Page 79594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by emailing
the indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Metallic Nanoparticles for Photothermal Therapy
Description of Technology: The invention relates to the preparation
and application of 20-150nm metallic nanoparticulate vesicles for
photothermal anti-cancer therapy. The vesicles comprise metallic
nanoparticles covalently bound to a hydrophilic and hydrophobic
polymer. The preparation method generally entails dispersing a polymer-
bound metallic nanoparticle in an organic solvent, adding an aqueous
solution with a dispersing aid, sonicating the mixture, and finally
removing the organic solvent until the vesicle forms. The final vesicle
is stable wherein the metallic nanoparticle is covalently bound to the
hydrophobic and hydrophilic polymer. By way of a non-limiting example,
an exemplary vesicles can be one made from gold nanorods coated with
polyethylene glycol and polylactic-co-glycolic acid (AuNR@PEG/PLGA) in
an oil-in-water emulsion.
Potential Commercial Applications:
Cancer therapy
Tumor therapy
Competitive Advantages:
Prolonged circulation
High tumor accumulation
Rapid excretion
Enhanced photoacoustic signal
Enhanced photothermal effect/cancer therapy efficacy.
Development Stage:
In vitro data
Inventors: Xiaoyuan (Shawn) Chen and Jibin Song (both of NIBIB).
Intellectual Property: HHS Reference No. E-158-2015/0-US-01.
U.S. Provisional Patent Application 62/226,289 filed
December 11, 2015.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering seeks statements of capability or
interest from parties interested in collaborative research to further
develop and evaluate metallic nanoparticle vesicles for cancer
phototherapy. For collaboration opportunities, please contact Cecilia
Pazman, Ph.D. at pazmance@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2015-32096 Filed 12-21-15; 8:45 am]
BILLING CODE 4140-01-P
